<DOC>
	<DOC>NCT02121444</DOC>
	<brief_summary>This study aims to investigate adherence to therapy among patients treated with Betaferon who are using the BETACONNECT autoinjector.</brief_summary>
	<brief_title>BAY86-5046 (Betaseron), Non Interventional Studies</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome. Patients must be on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician. Patient and attending physicians must have agreed on the usage of the BETACONNECT autoinjector device Written informed consent must be obtained. Patients receiving any other disease modifying drug. Contraindications of Betaferon described in the Summary of Product Characteristics.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>RRMS</keyword>
	<keyword>CIS</keyword>
</DOC>